Octreotide lowers gastric mucosal blood flow in normal and portal hypertensive stomachs.

Article Details

Citation
Copy to clipboard

Clarke DL, McKune A, Thomson SR

Octreotide lowers gastric mucosal blood flow in normal and portal hypertensive stomachs.

Surg Endosc. 2003 Oct;17(10):1570-2. doi: 10.1007/s00464-002-9274-z. Epub 2003 Jul 21.

PubMed ID
12874677 [ View in PubMed
]
Abstract

BACKGROUND: The vasoactive peptide octreotide has an established role in controlling variceal hemorrhage. The mechanism of action is believed to be a reduction in splanchnic blood flow. A decrease in splanchnic blood flow should be mirrored by a decrease in gastric mucosal blood flow (GMBF). Laser Doppler flowmetry (LDF) should detect changes in GMBF. METHODS: In seven normal volunteers and four patients with portal hypertension, 100 micro g of octreotide was administered as an intravenous bolus. Continuous LDF measurements were then made at a single point on the midantrum for at least 10 min and plotted against time for each subject. RESULTS: After a variable period of stabilization, GMBF decreased in all subjects except one. This was statistically significant in both the controls and the patients with portal hypertension. CONCLUSIONS: Octreotide decreases GMBF in normal and portal hypertensive stomachs. Laser Doppler is a useful and minimally invasive tool to assess the effect of drugs on GMBF.

DrugBank Data that Cites this Article

Drugs